Novocure (NVCR) Q4 2025 earnings review
Core Business Steady, But Multi-Indication Pivot Shows Friction
Novocure closed 2025 with $174.4M in Q4 revenue (+8% YoY), capping a year that successfully transitioned the company from a single-indication to a multi-indication oncology player. A major highlight arrived post-quarter with the FDA approval of Optune Pax for pancreatic cancer. However, the foundational financial narrative is mixed. While active patient counts in the core GBM segment (Optune Gio) are accelerating, the highly anticipated NSCLC launch (Optune Lua) remains sluggish, struggling to gain meaningful traction. Furthermore, FY26 guidance projects decelerating revenue growth (~5.3% at the midpoint) and ongoing Adjusted EBITDA losses, indicating the path to sustainable profitability will require more time and capital than previously anticipated.
🐂 Bull Case
The February 2026 FDA approval for locally advanced pancreatic cancer validates the pipeline and unlocks a major new TAM. This de-risks a crucial pillar of the company's multi-indication strategy.
The legacy Optune Gio business added 187 active patients in Q4, reaching 4,464. This represents an accelerating sequential growth rate and proves the core franchise's resilience.
🐻 Bear Case
Optune Lua prescriptions for NSCLC were flat at 118 in Q4, and active patients only increased by 22 sequentially to 122. The initial launch momentum has stalled significantly.
FY26 revenue guidance of $675-$705M implies a ~5.3% growth rate, a clear deceleration from the 8% growth achieved in FY25, pushing out profitability timelines.
⚖️ Verdict: ⚪
Neutral. The pipeline delivery (pancreatic cancer approval) and clean balance sheet are highly commendable, but the operational realities of launching new device indications into competitive drug markets (like NSCLC) are proving tougher and more expensive than expected.
Key Themes
Optune Pax FDA Approval Opens New Frontier
In February 2026, the FDA approved Optune Pax for locally advanced pancreatic cancer, used concurrently with standard chemotherapy. This marks a massive regulatory victory following the PANOVA-3 clinical trial. Because pancreatic cancer has notoriously poor survival rates and limited treatment innovations, this launch represents Novocure's strongest potential growth engine. The company guided $15-$25M in collective revenue for Optune Lua and Optune Pax in FY26, suggesting initial commercial adoption will be measured but deliberate.
Optune Lua (NSCLC) Launch Headwinds Persist
Management previously admitted the NSCLC launch was 'harder than we expected,' and Q4 data confirms this stable, sluggish trend. The company recorded 118 NSCLC prescriptions in Q4, effectively flatlining. Total active NSCLC patients grew from 100 in Q3 to just 122 in Q4. Furthermore, Novocure's decision to stop reporting new prescription data in Q1 2026 for indications commercially available for over a year (which includes NSCLC) may be interpreted by the market as a move to mask this lack of momentum.
Core GBM Business Demonstrates Impressive Resilience
While attention is focused on new launches, Optune Gio (GBM) continues to silently power the financials. Active patients reached 4,464, accelerating sequentially. International markets are critical here, with Japan and France maintaining robust footprints. The stable generation from GBM is providing the cash necessary to fund the multi-indication commercial rollouts.
Executive Turnover and Administrative Hurdles
A sudden string of organizational changes requires monitoring. Frank Leonard was elevated from President to CEO in December 2025. Additionally, the Chief Medical Officer resigned in February 2026. Operationally, the company revealed that its billing privileges with CMS were revoked retroactively to December 17, 2025, due to an administrative re-validation issue, though they were fully reinstated by late February 2026. While management expects no revenue impact, these combined friction points create execution risks during a critical launch phase.
Gross Margin Trough Passed, But Pressure Remains
Gross margin reversed its declining trend, climbing to 76% in Q4 from a trough of 73% in Q3. However, this is still below the 79% seen a year ago. The company attributes the ongoing structural pressure to the rollout of new Head Flexible Electrode (HFE) arrays, treating NSCLC patients prior to established reimbursement, and higher tariffs. FY26 guidance projects 'mid-70s' gross margins, meaning no quick return to historical ~80% levels.
Other KPIs
Decreased sharply from over $1.03B in Q3 due to the planned repayment of $561 million in convertible notes that matured in November 2025. The balance sheet is now significantly de-risked, and current liquidity is sufficient to fund operations and upcoming commercial launches.
Accelerating. Up 19% YoY, driven by higher clinical trial costs specifically associated with the KEYNOTE D58 and LUNAR-2 trials. Management continues to invest heavily in expanding the clinical utility of TTFields into first-line treatments alongside immune checkpoint inhibitors.
Reversing downward sequentially from $(3.0) million in Q3, despite higher revenues. This reflects the intense upfront operational and marketing costs associated with preparing for the Optune Pax launch and ongoing efforts to establish the NSCLC market.
Guidance
Decelerating. The midpoint of $690M implies a 5.3% YoY growth rate, stepping down from the 8.0% growth achieved in FY25. This reflects a conservative 'low-to-mid single digit' growth expectation for the core Optune Gio business.
Improving. The midpoint of $(10)M implies progress toward the company's stated goal of achieving sustainable Adjusted EBITDA profitability by 2027, cutting the FY25 loss of $(34.3)M by more than half.
Accelerating, but off a very low base. Compares to the $3.5M recognized in Q4 from Optune Lua. This conservative target indicates that the new indications will take time to secure reimbursement and ramp volume before becoming major financial pillars.
Key Questions
NSCLC Trajectory
With the decision to stop reporting new prescriptions for older indications in Q1 2026, how will investors transparently track the success or failure of the Optune Lua launch going forward?
Executive Transitions
With the recent CEO transition and the sudden resignation of the CMO right around the Optune Pax FDA approval, what strategic or structural shifts are taking place within the clinical organization?
Path to 2027 Profitability
Management previously anchored on a $700-$750M revenue run-rate for achieving sustainable Adjusted EBITDA breakeven in 2027. With FY26 revenue guided at $690M at the midpoint, is the timeline for profitability being pushed back, or are further cost-cutting measures planned?
Reimbursement Bottlenecks
What specific milestones are you tracking in 2026 to convert 'at-risk' Optune Lua and Optune Pax patients into fully reimbursed revenue streams?